^
BIOMARKER:

Inflammatory gene signature

1m
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. (PubMed, J Immunother Cancer)
The development of effective IDH1-targeting vaccine may be enhanced by integration with HLA class I-restricted cytotoxic T cell epitopes and AG-881. Our HLA-A2/HLA-DR1-syngeneic IDH1 glioma model should allow us to evaluate key translational questions related to the development of novel strategies for patients with IDH-mutant glioma.
Preclinical • Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
IDH1 mutation • IDH2 mutation • IFNG expression • Inflammatory gene signature • IDH1 R132
|
vorasidenib (AG-881)
2ms
A Novel Pyroptotic and Inflammatory Gene Signature Predicts the Prognosis of Cutaneous Melanoma and the Effect of Anticancer Therapies. (PubMed, Front Med (Lausanne))
Our novel 8-GRIP signature can accurately predict the prognosis of patients with CM and the efficacies of multiple anticancer therapies. These GRIPs might be potential prognostic biomarkers and therapeutic targets for CM.
Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • NLRP6 (NLR Family Pyrin Domain Containing 6) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • IL15 (Interleukin 15)
|
PD-1 expression • Inflammatory gene signature • CTLA4 expression
2ms
Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model. (PubMed, Mol Cancer Ther)
Contradictory, low and high-dose TRT decreased CD4pos T helper 1 (Th1)-cells in addition to double negative T-cells. In conclusion, these data suggest that low and high-dose TRT induce distinct immunological changes, which might serve as an anchoring point for combination therapy.
Preclinical • Journal
|
PD-L2 (Programmed Cell Death 1 Ligand 2) • CALR (Calreticulin) • IL10 (Interleukin 10)
|
CD20 expression • Inflammatory gene signature
2ms
Genomic profiling and outcomes of BRAF V600E mutated papillary thyroid cancer. (ASCO 2022)
Our data highlights new genomic signatures that indicate potential new, while also validating current targets for BRAFmut PTC: higher PD-L1 expression, immune infiltrate, and inflammatory gene signature. Clinical trials are needed to assess the best sequencing of therapies used in this group, particularly TKIs vs BRAF inhibitors and the role of immunotherapy.
PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
|
PD-L1 expression • BRAF V600E • PD-L1 overexpression • BRAF mutation • BRAF V600 • BRAF wild-type • Inflammatory gene signature
|
PD-L1 IHC 22C3 pharmDx
3ms
Characterization of urine-derived immune cells from bladder cancer patients and comparison to tumor and peripheral blood (IMMUNOLOGY 2022)
 Our work represents the first scRNAseq and CITE-seq of cancer patient urine. Our study shows several immune cells shed in bladder cancer patient urine and suggests they look phenotypically similar to the TIME. This has implications for future clinical applications as urine can be sampled non-invasively in scenarios when tumor resection may not be feasible.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Inflammatory gene signature
3ms
Single-cell myeloid diversity in human fallopian tube and its implications for early high grade serous ovarian cancer (IMMUNOLOGY 2022)
Understanding tissue-of-origins immune microenvironment has a potential contribution to early cancer detection. We anticipate this work provides evidence of how myeloid cell plasticity induces tumorigenesis and can shape different tumor microenvironments.
BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IL1A (Interleukin 1, alpha)
|
Inflammatory gene signature • MHC-II expression
4ms
Intratumoral Density of Regulatory T Cells Is a Predictor of Host Immune Response and Chemotherapy Response Rate in Metastases from Colorectal Cancer (SSO 2022)
Tregs in CRC are associated with multiple pro-cancer pathways, but also with immune cell infiltration and immune response, as well as response to chemotherapy, particularly in metastatic tumors. Learning Objectives: Describe the role of regulatory T cells in moderating the host immune response to cancer cells. Understand the differences in gene expression between colorectal cancers which are infiltrated by a high versus low proportion of regulatory T cells.
PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • PD-L2 (Programmed Cell Death 1 Ligand 2) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • TGFB1 (Transforming Growth Factor Beta 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • BTLA (B And T Lymphocyte Associated) • IFNA1 (Interferon Alpha 1)
|
TP53 mutation • KRAS mutation • BRAF mutation • Inflammatory gene signature
|
Avastin (bevacizumab)
8ms
TLR7 ligation augments hematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signalling. (PubMed, Blood Adv)
Finally, we show that in highly purified human bone marrow samples from anaemic patients, imiquimod leads to an increase in erythroid output from myelo-erythroid progenitors and common myeloid progenitors. Our findings have both specific implications for the development of targeted therapeutics for del (5q) MDS and wider significance identifying a potential role for TLR7 ligation in modifying anaemia.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TLR8 (Toll Like Receptor 8) • TLR7 (Toll Like Receptor 7)
|
Chr del(5q) • Inflammatory gene signature
|
Zyclara (imiquimod)